Clinical trials recruiting for HNSCC

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
  NCT06305962 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
  NCT07462377 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
  NCT06789172 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
  NCT03526835 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors
  NCT07106827 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
  NCT05859074 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of YL202 in Selected Patients With Advanced Solid Tumors
  NCT06107686 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 82 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
  NCT04114136 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
  NCT06657222 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
  NCT05877430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations

Related conditions

Trials recruiting for HNSCC often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for HNSCC trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.